These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36335)

  • 1. The board-and-care home: does it deserve a bad press?
    van Putten T; Spar JE
    Hosp Community Psychiatry; 1979 Jul; 30(7):461-4. PubMed ID: 36335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sheltered care environments and resident characteristics on the development of social networks.
    Segal SP; Holschuh J
    Hosp Community Psychiatry; 1991 Nov; 42(11):1125-31. PubMed ID: 1743640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pilot project 'Soteria Berne'. Clinical experiences and results.
    Ciompi L; Dauwalder HP; Maier C; Aebi E; Trütsch K; Kupper Z; Rutishauser C
    Br J Psychiatry Suppl; 1992 Oct; (18):145-53. PubMed ID: 1356365
    [No Abstract]   [Full Text] [Related]  

  • 4. Future time perspective and daily occupations of persons with chronic schizophrenia in a board and care home.
    Suto M; Frank G
    Am J Occup Ther; 1994 Jan; 48(1):7-18. PubMed ID: 8116786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications for the pharmacotherapy of schizophrenia.
    Rep Group Adv Psychiatry (1984); 1992; (134):35-58. PubMed ID: 1348372
    [No Abstract]   [Full Text] [Related]  

  • 6. Douglas House. Seven years' experience of a community hostel ward.
    Creighton FJ; Hyde CE; Farragher B
    Br J Psychiatry; 1991 Oct; 159():500-4. PubMed ID: 1751859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences between chronic schizophrenic patients in the hospital and in the community.
    Soni SD; Mallik A; Reed P; Gaskell K
    Hosp Community Psychiatry; 1992 Dec; 43(12):1233-8. PubMed ID: 1360939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of an open-door policy combined with a structured activity programme on the residual symptoms of schizophrenic in-patients. A six-month randomised controlled trial in Yanbian, Jilin.
    Jin Z
    Br J Psychiatry Suppl; 1994 Aug; (24):52-7. PubMed ID: 7946232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the rehab scale in a Greek context.
    Zissi A; Barry M
    Int J Rehabil Res; 1997 Jun; 20(2):183-8. PubMed ID: 9226501
    [No Abstract]   [Full Text] [Related]  

  • 10. [Evolution of the social autonomy scale (EAS) in schizophrenic patients depending on their management].
    Leguay D; Rouillon F; Azorin JM; Gasquet I; Loze JY; Arnaud R; Dillenschneider A
    Encephale; 2010 Oct; 36(5):397-407. PubMed ID: 21035630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower-dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients.
    Smith RC
    Arch Gen Psychiatry; 1994 May; 51(5):427-9. PubMed ID: 7910013
    [No Abstract]   [Full Text] [Related]  

  • 12. Characteristics of patients selected for treatment on a schizophrenia research unit.
    Schreiber JL; Breier A; Pickar D
    Hosp Community Psychiatry; 1990 Apr; 41(4):441-3. PubMed ID: 1970550
    [No Abstract]   [Full Text] [Related]  

  • 13. [Domain-specific subjective quality of life and illness-related limitations of chronic schizophrenic patients].
    Lauer G; Stegmüller-Koenemund U
    Psychiatr Prax; 1994 Mar; 21(2):70-3. PubMed ID: 7910973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders.
    Helldin L; Kane JM; Karilampi U; Norlander T; Archer T
    Schizophr Res; 2007 Jul; 93(1-3):160-8. PubMed ID: 17395430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation.
    Leucht S; Davis JM; Engel RR; Kissling W; Kane JM
    Acta Psychiatr Scand Suppl; 2009; (438):7-14. PubMed ID: 19132961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive and negative symptoms in schizophrenia: where are the data?
    de Leon J; Simpson GM; Peralta V
    Biol Psychiatry; 1992 Mar; 31(5):431-4. PubMed ID: 1349829
    [No Abstract]   [Full Text] [Related]  

  • 18. Information processing and maintenance dose requirements in schizophrenia.
    Marder SR; Asarnow RF; Van Putten T
    Psychopharmacol Bull; 1988; 24(2):247-50. PubMed ID: 2905506
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical symptomatology and drug compliance in schizophrenic patients.
    Bartkó G; Herczeg I; Zádor G
    Acta Psychiatr Scand; 1988 Jan; 77(1):74-6. PubMed ID: 2894746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Social outcome.
    Leary J; Johnstone EC; Owens DG
    Br J Psychiatry Suppl; 1991 Oct; (13):13-20, 44-6. PubMed ID: 1840765
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.